Clinical Trial Update: Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating rituximab with dexamethasone for recurrent or refractory indolent non-Hodgkin lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)

Snippet

Sponsor: Hoag Memorial Hospital Presbyterian | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN